21comM

The Best Performing ISA-Eligible ETFs & Funds Last Month

Equities 3 minutes to read
Neil Wilson
Neil Wilson

Investor Content Strategist

Note: This is marketing material. This article is not investment advice, capital is at risk.

The Best Performing ISA-Eligible ETFs & Funds Last Month

Key Points

  • China and emerging markets gain traction after Q2’s dollar weakness
  • Clean energy and biotechnology funds also did well
  • Vanguard FTSE All-World UCITS ETF is most traded at Saxo

Several themes emerged from our best performing ISA-eligible ETFs last month. One is the performance of emerging markets, which have been attracting inflows following the US dollar’s move lower in Q2, despite concerns about tariffs weighing on economic growth prospects.

Asia stood out in July, albeit there is a question about whether this will continue in light of tariffs. Thailand was hit with a 36% tariff on 2 April, but by the 1 August deadline this had been cut to 19%. Thailand’s stock market hit a five-year low a month ago on political upheaval but roared higher through July and indicators suggest a relief over the level of tariffs being imposed. Meanwhile a slew of China-focused funds made the top-performing list for the month as benchmarks in the mainland rose 3-5% over the month as investors pin hopes on a deal being done between the US and China on trade.

Top Performing ISA ETFs of the last month

Xtrackers MSCI Thailand UCITS ETF 

Xtrackers MSCI Korea UCITS ETF

Amundi MSCI China Tech UCITS ETF

Invesco EURO STOXX Optimised Bank UCITS ETF

Xtrackers MSCI China UCITS ETF

HSBC MSCI China UCITS ETF

Invesco S&P China A MidCap 500 Swap UCITS ETF

L&G Pharma Breakthrough UCITS ETF

Xtrackers MSCI USA Information Tech UCITS ETF

IShares S&P 500 Utilities Sector ETF

(Source: Saxo Investor, %1m change, ISA-eligible equity ETFs with a minimum 3-star Morningstar rating)

Among the top ISA-eligible Mutual Funds of the last month the best performers were the Polar Capital Biotechnology Fund, Polar Capital Global Technology, Franklin Templeton’s Biotechnology Discovery Fund and the China-focused Abrdn SICAV I – ALL A.

Among Saxo clients most bought ETFs in July were the Vanguard FTSE All-World UCITS ETF, the Vanguard S&P 500 Dist UCITS ETF and the Invesco QQQ Trust, Series 1 ETF.

For single stock investment ideas read our client trends report for July.


 

 

Quarterly Outlook

01 /

  • Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Quarterly Outlook

    Q3 Investor Outlook: Beyond American shores – why diversification is your strongest ally

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    Quarterly Outlook

    Q3 Macro Outlook: Less chaos, and hopefully a bit more clarity

    John J. Hardy

    Global Head of Macro Strategy

    After the chaos of Q2, the quarter ahead should get a bit more clarity on how Trump 2.0 is impacting...
  • Equity outlook: The high cost of global fragmentation for US portfolios

    Quarterly Outlook

    Equity outlook: The high cost of global fragmentation for US portfolios

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: Commodities rally despite global uncertainty

    Quarterly Outlook

    Commodity Outlook: Commodities rally despite global uncertainty

    Ole Hansen

    Head of Commodity Strategy

  • Upending the global order at blinding speed

    Quarterly Outlook

    Upending the global order at blinding speed

    John J. Hardy

    Global Head of Macro Strategy

    We are witnessing a once-in-a-lifetime shredding of the global order. As the new order takes shape, ...
  • Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Quarterly Outlook

    Asset allocation outlook: From Magnificent 7 to Magnificent 2,645—diversification matters, now more than ever

    Jacob Falkencrone

    Global Head of Investment Strategy

  • Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    Quarterly Outlook

    Macro outlook: Trump 2.0: Can the US have its cake and eat it, too?

    John J. Hardy

    Global Head of Macro Strategy

  • Equity Outlook: The ride just got rougher

    Quarterly Outlook

    Equity Outlook: The ride just got rougher

    Charu Chanana

    Chief Investment Strategist

  • China Outlook: The choice between retaliation or de-escalation

    Quarterly Outlook

    China Outlook: The choice between retaliation or de-escalation

    Charu Chanana

    Chief Investment Strategist

  • Commodity Outlook: A bumpy road ahead calls for diversification

    Quarterly Outlook

    Commodity Outlook: A bumpy road ahead calls for diversification

    Ole Hansen

    Head of Commodity Strategy

None of the information provided on this website constitutes an offer, solicitation, or endorsement to buy or sell any financial instrument, nor is it financial, investment, or trading advice. Saxo Capital Markets UK Ltd. (Saxo) and the Saxo Bank Group provides execution-only services, with all trades and investments based on self-directed decisions. Analysis, research, and educational content is for informational purposes only and should not be considered advice nor a recommendation. Access and use of this website is subject to: (i) the Terms of Use; (ii) the full Disclaimer; (iii) the Risk Warning; and (iv) any other notice or terms applying to Saxo’s news and research.

Saxo’s content may reflect the personal views of the author, which are subject to change without notice. Mentions of specific financial products are for illustrative purposes only and may serve to clarify financial literacy topics. Content classified as investment research is marketing material and does not meet legal requirements for independent research.

Before making any investment decisions, you should assess your own financial situation, needs, and objectives, and consider seeking independent professional advice. Saxo does not guarantee the accuracy or completeness of any information provided and assumes no liability for any errors, omissions, losses, or damages resulting from the use of this information.

Please refer to our full disclaimer for more details. Past Performance is not indicative of future results.

Saxo
40 Bank Street, 26th floor
E14 5DA
London
United Kingdom

Contact Saxo

Select region

United Kingdom
United Kingdom

Trade Responsibly
All trading carries risk. To help you understand the risks involved we have put together a series of Key Information Documents (KIDs) highlighting the risks and rewards related to each product. Read more
Additional Key Information Documents are available in our trading platform.

Saxo is a registered Trading Name of Saxo Capital Markets UK Ltd (‘Saxo’). Saxo is authorised and regulated by the Financial Conduct Authority, Firm Reference Number 551422. Registered address: 26th Floor, 40 Bank Street, Canary Wharf, London E14 5DA. Company number 7413871. Registered in England & Wales.

This website, including the information and materials contained in it, are not directed at, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in the United States, Belgium or any other jurisdiction where such distribution, publication, availability or use would be contrary to applicable law or regulation.

It is important that you understand that with investments, your capital is at risk. Past performance is not a guide to future performance. It is your responsibility to ensure that you make an informed decision about whether or not to invest with us. If you are still unsure if investing is right for you, please seek independent advice. Saxo assumes no liability for any loss sustained from trading in accordance with a recommendation.

Apple, iPad and iPhone are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. Android is a trademark of Google Inc.

©   since 1992